Prestige Biopharma eyes at least 1.8t won valuation in Korean IPO
Biotech firm also plans to expand its headcount to about 300 in next five years
Add BT as a preferred source
Singapore
SINGAPORE-BASED Prestige Biopharma expects an implied market capitalisation of between 1.8 trillion won and 1.93 trillion won (S$2.2 billion to S$2.3 billion) in its upcoming initial public offering (IPO) on the Korea Exchange (KRX), the company told The Business Times.
As it looks to list early this year, the biotech firm also plans to expand its headcount from the current 70 to about 300 staff, possibly in the next five years, its chief executive Lisa Park told BT.
TRENDING NOW
Singapore Kitchen CEO, senior manager charged with alleged fraud, falsifying accounts; both to stay in jobs for now
Profit with purpose: Kim Choo Kueh Chang’s pivot from public listing to protecting heritage
Pet insurance demand still rising, but growth may be losing bite
Who would buy Vietnam’s state-owned stakes – when Hanoi is ready to sell?
